Policy responses and statements

Name of organisation:

Medicines and Healthcare Products Regulatory Agency (MHRA)

Name of policy document:

ARM 40: Request to Reclassify a Product from P to GSL - Canesten AF Bifonazole Once Daily Athlete's Foot Cream

Deadline for response:

26 March 2007

Background: Consultation document ARM 40 seeks views on the reclassification from P to GSL of Canesten AF Bifonzole Once Daily Athlete's Foot Cream. The active ingredient is Bifonazole 1% w/w. Bifonazole 1% Cream has been licensed in the UK since 1986, as a treatment for athlete's foot, initially as a prescription only medicine, with subsequent legal reclassification to Pharmacy status in 1997.

Download this consultation response as a .pdf

Copies of this response are available from:

Lesley Lockhart,
Royal College of Physicians of Edinburgh,
9 Queen Street,
Edinburgh,
EH2 1JQ.

Tel: 0131 225 7324 ext 608
Fax: 0131 220 3939

[5 February 2007]